Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved]
Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and socie...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2019-08-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-1371/v1 |
| _version_ | 1818198735770877952 |
|---|---|
| author | Burkhard Tümmler |
| author_facet | Burkhard Tümmler |
| author_sort | Burkhard Tümmler |
| collection | DOAJ |
| description | Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement. |
| first_indexed | 2024-12-12T02:10:36Z |
| format | Article |
| id | doaj.art-272e9ce700fc4922802098c2d57a867a |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-12T02:10:36Z |
| publishDate | 2019-08-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-272e9ce700fc4922802098c2d57a867a2022-12-22T00:41:54ZengF1000 Research LtdF1000Research2046-14022019-08-01810.12688/f1000research.19509.121389Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved]Burkhard Tümmler0Clinical Research Group ‘Molecular Pathology of Cystic Fibrosis’ and ‘Pseudomonas Genomics’, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, 30625, GermanyInfections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.https://f1000research.com/articles/8-1371/v1 |
| spellingShingle | Burkhard Tümmler Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] F1000Research |
| title | Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] |
| title_full | Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] |
| title_fullStr | Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] |
| title_full_unstemmed | Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] |
| title_short | Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved] |
| title_sort | emerging therapies against infections with pseudomonas aeruginosa version 1 peer review 2 approved |
| url | https://f1000research.com/articles/8-1371/v1 |
| work_keys_str_mv | AT burkhardtummler emergingtherapiesagainstinfectionswithpseudomonasaeruginosaversion1peerreview2approved |